Osteoarthritis
Clinicians have 'reason for optimism' in novel osteoarthritis therapies
A number of compounds and therapeutic approaches moving through the pipeline may soon enrich treatment paradigms for osteoarthritis, according to a presenter at the 2020 Congress of Clinical Rheumatology-East.
Canakinumab may reduce total knee, hip replacement, OA symptoms
Interleukin-1 inhibition with canakinumab may substantially reduce rates of total hip and knee replacement, as well as osteoarthritis symptoms, according to data published in the Annals of Internal Medicine.
Patients with OA prefer therapy focus on disease progression with benefit to pain, walking
When presented with a range of treatment options, patients with osteoarthritis reported that the most important outcomes are disease progression and improving pain and walking, noted researchers in Seminars in Arthritis and Rheumatism.
Unproven ‘stem cell therapy’ claims spread beyond arthritis into COVID-19
Nature abhors a vacuum, and in the absence of evidence-based therapies to treat or prevent COVID-19, stem cell clinics with a menu of unsubstantiated direct-to-consumer therapies are more than willing to fill the gap.
Physically demanding jobs linked to increased odds of knee OA
Occupations with heavy physical labor, such as cleaning, agricultural, service, house and construction work, as well as mining, are associated with greater odds of developing knee osteoarthritis, according to data published in Arthritis Care and Research.
Vitamin D, omega-3 fatty acids supplements over 5 years fail to reduce knee pain
Treatment with vitamin D and omega-3 fatty acids supplements for a mean duration of 5.3 years failed to reduce chronic knee pain or improve function or stiffness, according to data published in Arthritis & Rheumatology.
CDC recognizes 30th anniversary of Americans with Disabilities Act
This year marks the 30th anniversary of the Americans with Disabilities Act, signed into law by President George H.W. Bush on July 26, 1990.
Ticagrelor linked to 29% lower risk for osteoarthritis than clopidogrel
Ticagrelor was associated with a 29% lower risk for osteoarthritis compared with another antiplatelet agent, clopidogrel, during a 5-year follow-up period, according to data published in Arthritis & Rheumatology.
CBT, placebo inferior to NSAIDs for knee osteoarthritis
In patients with knee osteoarthritis, placebo followed by cognitive behavioral therapy were inferior to meloxicam, according to research published in JAMA Internal Medicine.
Opioids offer minimal benefit to pain, function in OA, no aid to QoL
Opioids offer only minimal relief of osteoarthritis symptoms within a 12-week period, and cause discomfort in most patients, according to findings published in Arthritis Care & Research.